Divi's Laboratories Toekomstige groei

Future criteriumcontroles 4/6

Divi's Laboratories zal naar verwachting groeien in winst en omzet met respectievelijk 21.9% en 14.7% per jaar. De winst per aandeel zal naar verwachting groeien met 22% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 16.6% zijn.

Belangrijke informatie

21.9%

Groei van de winst

22.0%

Groei van de winst per aandeel

Life Sciences winstgroei	21.4%
Inkomstengroei	14.7%
Toekomstig rendement op eigen vermogen	16.6%
Dekking van analisten	Good
Laatst bijgewerkt	19 Oct 2024

Recente toekomstige groei-updates

Earnings Miss: Divi's Laboratories Limited Missed EPS By 9.1% And Analysts Are Revising Their Forecasts

Aug 06

The Divi's Laboratories Limited (NSE:DIVISLAB) Yearly Results Are Out And Analysts Have Published New Forecasts

Jul 19

Recent updates

Revenues Not Telling The Story For Divi's Laboratories Limited (NSE:DIVISLAB)

Sep 06

Earnings Miss: Divi's Laboratories Limited Missed EPS By 9.1% And Analysts Are Revising Their Forecasts

Aug 06

The Divi's Laboratories Limited (NSE:DIVISLAB) Yearly Results Are Out And Analysts Have Published New Forecasts

Jul 19

Shareholders Should Be Pleased With Divi's Laboratories Limited's (NSE:DIVISLAB) Price

Apr 19

Divi's Laboratories' (NSE:DIVISLAB) Shareholders Will Receive A Bigger Dividend Than Last Year

Jul 21

Divi's Laboratories (NSE:DIVISLAB) Will Pay A Larger Dividend Than Last Year At ₹30.00

Jul 07

Here's Why We Think Divi's Laboratories (NSE:DIVISLAB) Might Deserve Your Attention Today

Jul 03

Does Divi's Laboratories (NSE:DIVISLAB) Deserve A Spot On Your Watchlist?

Apr 03

Should You Be Adding Divi's Laboratories (NSE:DIVISLAB) To Your Watchlist Today?

Dec 23

With EPS Growth And More, Divi's Laboratories (NSE:DIVISLAB) Is Interesting

Sep 02

Winst- en omzetgroeiprognoses

NSEI:DIVISLAB - Toekomstschattingen van analisten en financiële gegevens uit het verleden (INR Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
3/31/2027	122,748	30,675	18,612	N/A	14
3/31/2026	106,396	26,142	12,413	N/A	26
3/31/2025	91,038	20,701	7,442	N/A	24
6/30/2024	81,850	16,740	N/A	N/A	N/A
3/31/2024	78,450	16,000	2,580	12,610	N/A
12/31/2023	74,926	13,834	N/A	N/A	N/A
9/30/2023	73,456	13,314	7,927	15,127	N/A
6/30/2023	72,906	14,774	N/A	N/A	N/A
3/31/2023	77,670	18,240	19,860	24,590	N/A
12/31/2022	83,353	23,971	N/A	N/A	N/A
9/30/2022	91,208	29,925	22,153	28,404	N/A
6/30/2022	92,538	31,054	N/A	N/A	N/A
3/31/2022	89,599	29,605	11,986	19,118	N/A
12/31/2021	82,297	25,678	N/A	N/A	N/A
9/30/2021	74,379	21,362	4,760	13,465	N/A
6/30/2021	71,996	20,493	N/A	N/A	N/A
3/31/2021	69,695	19,843	10,367	19,469	N/A
12/31/2020	65,710	18,705	N/A	N/A	N/A
9/30/2020	62,658	17,590	10,714	20,167	N/A
6/30/2020	59,620	15,962	N/A	N/A	N/A
3/31/2020	53,945	13,765	327	12,159	N/A
12/31/2019	52,719	12,803	N/A	N/A	N/A
9/30/2019	52,356	13,106	-3,430	7,962	N/A
6/30/2019	51,139	13,575	N/A	N/A	N/A
3/31/2019	49,463	13,527	2,212	9,543	N/A
3/31/2018	38,915	8,770	N/A	7,759	N/A
3/31/2017	40,643	10,604	N/A	11,504	N/A
3/31/2016	37,764	11,258	N/A	10,379	N/A
3/31/2015	31,049	8,515	N/A	8,263	N/A
3/31/2014	25,267	7,733	N/A	5,567	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei DIVISLAB ( 21.9% per jaar) ligt boven de spaarquote ( 6.7% ).

Winst versus markt: De winst van DIVISLAB ( 21.9% per jaar) zal naar verwachting sneller groeien dan de Indian markt ( 18.1% per jaar).

Hoge groeiwinsten: De winst van DIVISLAB zal naar verwachting de komende 3 jaar aanzienlijk groeien.

Omzet versus markt: De omzet van DIVISLAB ( 14.7% per jaar) zal naar verwachting sneller groeien dan de markt Indian ( 10.2% per jaar).

Hoge groei-inkomsten: De omzet van DIVISLAB ( 14.7% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen DIVISLAB zal naar verwachting over 3 jaar laag zijn ( 16.6 %).

Divi's Laboratories Toekomstige groei

Future criteriumcontroles 4/6

Belangrijke informatie

Recente toekomstige groei-updates

Earnings Miss: Divi's Laboratories Limited Missed EPS By 9.1% And Analysts Are Revising Their Forecasts

Price target increased by 9.6% to ₹4,300

The Divi's Laboratories Limited (NSE:DIVISLAB) Yearly Results Are Out And Analysts Have Published New Forecasts

Price target increased by 11% to ₹3,806

Consensus EPS estimates fall by 10%

Price target increased by 7.3% to ₹3,325

Recent updates

Divi's Laboratories Limited to Report Q2, 2025 Results on Nov 09, 2024

Revenues Not Telling The Story For Divi's Laboratories Limited (NSE:DIVISLAB)

Chief Technologist - PDSC recently sold ₹9.8m worth of stock

Insider recently sold ₹59m worth of stock

Divi's Laboratories Limited Declares Dividend for the Financial Year Ended March 31, 2024

Earnings Miss: Divi's Laboratories Limited Missed EPS By 9.1% And Analysts Are Revising Their Forecasts

Price target increased by 9.6% to ₹4,300

Upcoming dividend of ₹30.00 per share

Divi's Laboratories Limited to Report Q1, 2025 Results on Aug 03, 2024

The Divi's Laboratories Limited (NSE:DIVISLAB) Yearly Results Are Out And Analysts Have Published New Forecasts

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Divi's Laboratories Limited Announces Board and Committee Changes

Insider recently sold ₹46m worth of stock

Insider recently sold ₹238m worth of stock

Dividend of ₹30.00 announced

Price target increased by 11% to ₹3,806

Divi's Laboratories Limited Recommends A Final Dividend for the Financial Year 2023-24

Divi's Laboratories Limited to Report Q4, 2024 Results on May 25, 2024

Shareholders Should Be Pleased With Divi's Laboratories Limited's (NSE:DIVISLAB) Price

Divi's Laboratories Limited Approves Appointment of Dr. S. Devendra Rao as Whole-Time Director (Manufacturing)

Insider recently sold ₹24m worth of stock

Chief Technologist recently sold ₹56m worth of stock

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Divi's Laboratories Limited to Report Q3, 2024 Results on Feb 10, 2024

Insider recently sold ₹59m worth of stock

Divi's Laboratories Limited (NSE:DIVISLAB) Not Flying Under The Radar

Non-Executive Independent Director recently sold ₹1.4m worth of stock

Consensus EPS estimates fall by 10%

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Divi's Laboratories Limited to Report Q2, 2024 Results on Nov 06, 2023

Insider recently sold ₹3.3m worth of stock

Chief Technologist recently sold ₹2.9m worth of stock

Divi's Laboratories Limited Declares Dividend for the Financial Year Ended March 31, 2023

Divi's Laboratories Limited Informs Resignations of Directors

Price target increased by 7.3% to ₹3,325

New minor risk - Profit margin trend

Insufficient new directors

Divi's Laboratories Limited to Report Q1, 2024 Results on Aug 14, 2023

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Upcoming dividend of ₹30.00 per share at 0.8% yield

Divi's Laboratories (NSE:DIVISLAB) Will Pay A Dividend Of ₹30.00

Divi's Laboratories (NSE:DIVISLAB) Will Pay A Dividend Of ₹30.00

New minor risk - Insider selling

Divi's Laboratories (NSE:DIVISLAB) Has Announced A Dividend Of ₹30.00

Divi's Laboratories Limited, Annual General Meeting, Aug 28, 2023

Insider recently sold ₹3.4m worth of stock

Divi's Laboratories Limited Recommends a Dividend for the Financial Year 2022-23

Full year 2023 earnings released: EPS: ₹68.69 (vs ₹112 in FY 2022)

Divi's Laboratories Limited to Report Q4, 2023 Results on May 20, 2023

Insider recently sold ₹2.0m worth of stock

Global Quality Head recently sold ₹2.3m worth of stock

Global Quality Head recently sold ₹2.8m worth of stock

Global Quality Head recently sold ₹28m worth of stock

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates fall by 15%

Divi's Laboratories Limited to Report Q3, 2023 Results on Feb 03, 2023

Board Member recently sold ₹10m worth of stock

MD & Executive Director recently sold ₹1.0m worth of stock

Insider recently sold ₹1.7m worth of stock

Insider recently sold ₹1.2m worth of stock

Consensus EPS estimates fall by 12%

Price target decreased to ₹3,582

Price target decreased to ₹3,685

Price target decreased to ₹3,685

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Is Now The Time To Put Divi's Laboratories (NSE:DIVISLAB) On Your Watchlist?

Insider recently sold ₹1.5m worth of stock

Insider recently sold ₹3.7m worth of stock

Upcoming dividend of ₹30.00 per share